Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - CCDC6 FGFR3 - TACC3||adrenal carcinoma||predicted - sensitive||Erdafitinib||Case Reports/Case Series||Actionable||In a Phase I trial, Balversa (erdafitinib) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3-TACC3 and FGFR2-CCDC6 fusions (PMID: 26324363; NCT01703481).||26324363|
|FGFR2 - CCDC6 FGFR2 N549D FGFR2 N549K FGFR2 V564I||cholangiocarcinoma||predicted - resistant||Pemigatinib||Case Reports/Case Series||Actionable||In a Phase I trial (FIGHT-101), a cholangiocarcinoma patient harboring FGFR2-CCDC6 experienced disease progression after initially responding to Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K, FGFR2 N549D, and FGFR2 V564I (PMID: 35176457; NCT02393248).||35176457|